BNB Plus Corp had announced that its biopharmaceutical arm, LineaRx, has secured two new orders for its LineaDNA product from established genetic medicine developers. Production and shipment for both orders are expected to be completed before June 2026.

 

“We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our continued engagements with top-tier customers demonstrates both the technical excellence of our LineaDNA platform and our continued operational execution."

 

The announcement follows a record-setting $1.2 million accelerated LineaDNA order, the largest in the company’s history. LineaRx now projects more than $1.5 million in LineaDNA shipments to the diagnostic and genetic medicines markets in the first half of 2026, with roughly 8 grams of DNA slated for delivery this quarter alone.

 

BNBX also highlighted its ongoing focus on operational efficiency. Cost reduction initiatives across the legacy LineaRx business are expected to save approximately $3 million annually, while a move to a smaller corporate headquarters adds another $600,000 in anticipated yearly savings.

 

Building on these efficiencies and manufacturing momentum, the company said it anticipates strong financial performance from LineaRx in FY26Q2 and beyond.